Recurrent Multiple Myeloma Clinical Trials

10 recruiting

Frequently Asked Questions

Common questions about Recurrent Multiple Myeloma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Refractory Multiple MyelomaRecurrent Multiple Myeloma
National Cancer Institute (NCI)26 enrolled14 locationsNCT06465316
Recruiting
Phase 1

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

Multiple MyelomaRefractory Multiple MyelomaRecurrent Multiple Myeloma
Thomas Martin, MD30 enrolled1 locationNCT07340853
Recruiting
Phase 1Phase 2

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma

Refractory Multiple MyelomaRecurrent Multiple Myeloma
Fred Hutchinson Cancer Center30 enrolled1 locationNCT07181941
Recruiting
Phase 2

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple MyelomaRecurrent Multiple Myeloma
Mayo Clinic44 enrolled1 locationNCT06940297
Recruiting
Phase 2

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

Refractory Multiple MyelomaRecurrent Multiple Myeloma
Mayo Clinic62 enrolled1 locationNCT05847569
Recruiting
Phase 1

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Refractory Multiple MyelomaRecurrent Multiple Myeloma
Abdullah Khan27 enrolled1 locationNCT05981209
Recruiting
Phase 2

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Refractory Multiple MyelomaRecurrent Multiple MyelomaExtramedullary Disease in Multiple Myeloma
Roswell Park Cancer Institute28 enrolled1 locationNCT06627751
Recruiting
Phase 1Phase 2

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Recurrent Multiple Myeloma
Mayo Clinic37 enrolled1 locationNCT06785415
Recruiting
Not Applicable

Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma

Refractory Multiple MyelomaRecurrent Multiple Myeloma
Mayo Clinic20 enrolled1 locationNCT07045727
Recruiting
Phase 1

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple MyelomaRecurrent Multiple Myeloma
Roswell Park Cancer Institute15 enrolled1 locationNCT06622005